Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Oral HPV-DNA Persists after Oropharyngeal Cancer Treatment

By LabMedica International staff writers
Posted on 14 May 2019
Head and neck cancers affect some 53,000 people in the USA each year, according to the National Cancer Institute, and human papilloma virus (HPV) has been implicated in many of those cases. More...
The diagnosis of cancer can be confirmed by tissue biopsy.

In general, patients with HPV-positive tumors have higher survival rates than those with HPV-negative tumors. Persistent traces of human papilloma virus DNA after treatment for HPV-positive head and neck cancer are linked to an increased recurrence risk.

Medical scientists at the Johns Hopkins School of Medicine (Baltimore, MD, USA) and the MD Anderson Cancer Center (Houston, TX, USA) and their colleagues performed a prospective, two-institution, tertiary referral center study of 396 patients with newly diagnosed oral cavity or oropharyngeal head and neck squamous cell carcinoma (HNSCC) from July 11, 2011, to May 7, 2016.

Oral rinse samples were prospectively collected at diagnosis and at completion of primary therapy. Weekly oral rinse samples were collected during radiotherapy. Purified tumor and oral rinse sample DNA were evaluated for 37 HPV types, and viral load was quantified by type-specific real-time polymerase chain reaction. Cancers were stratified by tumor HPV status, and HPV was classified as tumor type if identical to that detected in the tumor or non-tumor type.

The investigators reported that at diagnosis, patients with HPV-positive tumors were significantly more likely to have oral rinse samples positive for HPV than were patients with HPV-negative tumors. In particular, the scientists reported that the detection of any oral HPV DNA had a sensitivity of 84%, a specificity of 88%, a positive predictive value of 88%, and a negative predictive value of 84% for the diagnosis of an HPV-positive tumor. The prevalence of oral HPV DNA, though, went down after treatment. Prior to treatment, the prevalence of HPV DNA in oral rinses that matched that of HPV in the tumor sample was 69%. But after primary surgical resection, it was about 14%. Its prevalence fell similarly for patients who underwent radiotherapy, going from 85% before treatment to 9% after radiotherapy.

As expected, overall and recurrence-free survival was higher for patients with HPV-positive tumors than with HPV-negative tumors. Patients with HPV-positive tumors had a two-year overall survival of 91%, as compared to 75% for patients with HPV-negative tumors. But for a subset of patients with HPV-positive tumors, about 14%, the prevalence of oral HPV DNA did not decline with treatment. These patients were more likely to recurrent disease, with about 45% experiencing disease recurrence within two years. Additionally, this subset had a lower two-year overall survival of 68%.

The authors concluded that the prevalence and viral load of tumor-type HPV DNA decreased rapidly with therapy, and persistent detection was associated with increased risk of recurrence and death. Analysis of tumor type HPV DNA has considerable promise as a biomarker for treatment response and risk of progression. The study was published on May 2, 2019, in the journal JAMA Oncology.

Related Links:
Johns Hopkins School of Medicine
MD Anderson Cancer Center


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
βeta-Hydroxybutyrate Reagent
β-Hydroxybutyrate LiquiColor®
POC Immunoassay Analyzer
Procise DX
Gold Member
Clinical Chemistry Assay
Sorbitol Dehydrogenase (SDH)
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Researchers combined a blood-based biomarker of Alzheimer’s disease with age, sex, and genetic risk to estimate future cognitive impairment risk in asymptomatic adults (Image Credit: Adobe Stock)

Blood Biomarker Model May Help Estimate Five- and 10-Year Cognitive Impairment Risk

Estimating future cognitive impairment risk remains challenging in cognitively healthy adults, particularly when biomarker findings are reduced to simple positive or negative results. Because mild cognitive... Read more

Molecular Diagnostics

view channel
Image Credit: Shutterstock

Lung Cancer Atlas Reveals Cellular Patterns Associated With Patient Prognosis

Lung cancer is a leading cause of cancer-related death worldwide and is characterized by substantial cellular heterogeneity. Even within a single tumor, cancer cells can vary in aggressiveness, while immune,... Read more

Immunology

view channel
Image: The panel expands Cepheid’s respiratory testing portfolio on the GeneXpert platform, offering laboratories greater flexibility in selecting tests based on clinical needs. (Photo courtesy of Cepheid)

Multiplex PCR Test Gains CE Marking to Support Respiratory Infection Diagnosis

Acute respiratory infections often present with overlapping symptoms, making it difficult to distinguish between viral and bacterial causes. Seasonal surges of influenza-like illness in Europe further... Read more

Industry

view channel
Image: The TOMR trial uses Signatera-guided MRD testing to identify high-risk patients for curative-intent treatment.

Natera and Incyte Collaborate on MRD-Guided Colorectal Cancer Treatment Study

Natera (Austin, TX, USA) has entered into a clinical collaboration with Incyte (Wilmington, DE, USA) for a Phase II study evaluating molecular residual disease (MRD)-guided treatment in colorectal cancer.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.